2026-2034年全球放射性药物/核医市场规模、份额、趋势和成长分析报告

预计放射性药物/核医市场将从 2025 年的 217.8 亿美元成长到 2034 年的 395.1 亿美元，2026 年至 2034 年的复合年增长率为 6.84%。

全球放射性药物/核医市场持续稳定成长，这主要得益于核子医学扫描术诊断技术在疾病诊断和治疗中日益广泛的应用。放射性药物广泛应用于肿瘤学、心臟病学和神经病学领域，用于精准成像和标靶治疗。癌症和心血管疾病发生率的上升加速了对先进诊断工具的需求。 PET和SPECT等影像技术的进步正在提高诊断的准确性和早期检测能力。

关键成长要素包括医疗基础设施投资的增加和个人化医疗方法的广泛应用。放射性同位素生产和标靶放射治疗的技术创新正在扩大治疗应用范围。已开发地区人口老化显着推高了市场需求，因为老年人更容易患慢性疾病。新型放射性药物的监管核准进一步加速了市场扩张，并促进了製药公司在研发方面的投入。

将诊断和治疗相结合的治疗诊断学（诊断-治疗融合）方法的发展为未来带来了光明的前景。迴旋加速器设施的扩建和分销网络的改善将提高新兴市场的可近性。研究机构和医疗服务提供者之间的合作有望加速创新。随着精准癌症治疗的进步，放射性药物将成为标靶治疗策略的关键，并有望在未来几年推动其持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球放射性药物/核医市场：依应用领域划分

• 市场分析、洞察与预测
• 诊断
• 治疗用途

第五章 全球放射性药物/核医市场：依来源划分

• 市场分析、洞察与预测
• 核子反应炉
• 迴旋加速器

第六章 全球放射性药物/核医市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 诊断中心
• 癌症研究机构
• 门诊手术中心
• 其他的

第七章 全球放射性药物/核医市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Novartis AG
  • Siemens Healthineers AG
  • Bayer AG
  • GE HealthCare
  • Lantheus
  • Curium
  • Jubilant Radiopharma
  • Eckert & Ziegler
  • Cardinal Health
  • Telix Pharmaceuticals Limited
  • Bracco
  • Lilly
  • AstraZeneca

The Radiopharmaceutical/Nuclear Medicine Market size is expected to reach USD 39.51 Billion in 2034 from USD 21.78 Billion (2025) growing at a CAGR of 6.84% during 2026-2034.

The Global Radiopharmaceutical/Nuclear Medicine Market has grown steadily with increasing utilization of nuclear imaging techniques for disease diagnosis and treatment. Radiopharmaceuticals are widely used in oncology, cardiology, and neurology for precise imaging and targeted therapy. Rising prevalence of cancer and cardiovascular diseases has accelerated demand for advanced diagnostic tools. Improvements in imaging technologies such as PET and SPECT have enhanced accuracy and early detection capabilities.

Key drivers include growing investments in healthcare infrastructure and expanding adoption of personalized medicine approaches. Technological innovations in radioisotope production and targeted radiotherapy have broadened therapeutic applications. Aging populations in developed regions contribute significantly to demand, as older individuals are more prone to chronic diseases. Regulatory approvals for novel radiopharmaceutical agents further stimulate market expansion, encouraging pharmaceutical companies to invest in research and development initiatives.

Future prospects are promising with the development of theranostic approaches that combine diagnosis and therapy. Expansion of cyclotron facilities and improved distribution networks will enhance accessibility in emerging markets. Collaborations between research institutions and healthcare providers are expected to accelerate innovation. As precision oncology advances, radiopharmaceuticals will likely become integral to targeted treatment strategies, driving sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Diagnostic
• Therapeutic

By Source

• Nuclear Reactors
• Cyclotrons

By End User

• Hospitals
• Diagnostic Centers
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Others

COMPANIES PROFILED

• Novartis AG, Siemens Healthineers AG, Bayer AG, GE HealthCare, Lantheus, Curium, Jubilant Radiopharma, Eckert Ziegler, Cardinal Health, Telix Pharmaceuticals Limited, Bracco, Lilly, AstraZeneca

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Diagnostic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Nuclear Reactors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cyclotrons Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cancer Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Application
  • 7.2.2 By Source
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Application
  • 7.3.2 By Source
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Application
  • 7.4.2 By Source
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Application
  • 7.5.2 By Source
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Application
  • 7.6.2 By Source
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis AG
  • 9.2.2 Siemens Healthineers AG
  • 9.2.3 Bayer AG
  • 9.2.4 GE HealthCare
  • 9.2.5 Lantheus
  • 9.2.6 Curium
  • 9.2.7 Jubilant Radiopharma
  • 9.2.8 Eckert & Ziegler
  • 9.2.9 Cardinal Health
  • 9.2.10 Telix Pharmaceuticals Limited
  • 9.2.11 Bracco
  • 9.2.12 Lilly
  • 9.2.13 AstraZeneca